These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 23480466)
1. A review of in vitro and in vivo models of oesophageal and gastric cancer. Mukherji D; Benepal T Expert Opin Drug Discov; 2009 Dec; 4(12):1267-79. PubMed ID: 23480466 [TBL] [Abstract][Full Text] [Related]
2. Hsp90 as a therapeutic target in patients with oesophageal carcinoma. Ekman S; Bergqvist M; Tell R; Bergström S; Lennartsson J Expert Opin Ther Targets; 2010 Mar; 14(3):317-28. PubMed ID: 20148718 [TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal cancer: recent developments in medical oncology. Chong G; Cunningham D Eur J Surg Oncol; 2005 Jun; 31(5):453-60. PubMed ID: 15922879 [TBL] [Abstract][Full Text] [Related]
4. Advances in targeted therapeutic agents. Nicolaides NC; Sass PM; Grasso L Expert Opin Drug Discov; 2010 Nov; 5(11):1123-40. PubMed ID: 22827748 [TBL] [Abstract][Full Text] [Related]
6. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. State of the art: radiolabeled microspheres treatment for liver malignancies. Deleporte A; Flamen P; Hendlisz A Expert Opin Pharmacother; 2010 Mar; 11(4):579-86. PubMed ID: 20163269 [TBL] [Abstract][Full Text] [Related]
11. New and potential clinical applications of KRAS as a cancer biomarker. Kriegshäuser G; Auner V; Zeillinger R Expert Opin Med Diagn; 2010 Sep; 4(5):383-95. PubMed ID: 23496197 [TBL] [Abstract][Full Text] [Related]
12. Re-overcoming barriers in translating biomarkers to clinical practice. Staratschek-Jox A; Schultze JL Expert Opin Med Diagn; 2010 Mar; 4(2):103-12. PubMed ID: 23484444 [TBL] [Abstract][Full Text] [Related]
13. Blood-based peptide, genetic, and epigenetic biomarkers for diagnosing gastrointestinal cancers. Kraus S; Goel A; Arber N Expert Opin Med Diagn; 2010 Nov; 4(6):459-71. PubMed ID: 23496227 [TBL] [Abstract][Full Text] [Related]
14. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482 [TBL] [Abstract][Full Text] [Related]
15. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Bianchini D; Zivi A; Sandhu S; de Bono JS Expert Opin Investig Drugs; 2010 Dec; 19(12):1487-502. PubMed ID: 20868208 [TBL] [Abstract][Full Text] [Related]
16. Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research. Schütte U; Bisht S; Brossart P; Feldmann G Expert Opin Drug Discov; 2011 Jan; 6(1):33-48. PubMed ID: 22646825 [TBL] [Abstract][Full Text] [Related]
17. Lack of DMBT1 expression in oesophageal, gastric and colon cancers. Mori M; Shiraishi T; Tanaka S; Yamagata M; Mafune K; Tanaka Y; Ueo H; Barnard GF; Sugimachi K Br J Cancer; 1999 Jan; 79(2):211-3. PubMed ID: 9888459 [TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis type 1: diagnosis and recent advances. Upadhyaya M Expert Opin Med Diagn; 2010 Jul; 4(4):307-22. PubMed ID: 23496147 [TBL] [Abstract][Full Text] [Related]